In an SEC filing Friday, BioMimetic Therapeutics announced the resignation of Chief Science Officer Charles Hart, citing his desire to "continue to be involved in discovery research." Hart was named in 2004 and held the role during critical phases of the company's efforts to win FDA approval for its products. BioMimetic has struggled recently to recruit patients to participate in key clinical trials, but recently received FDA approval to stay on course. Our earlier reports chronicled BioMimetic's progress and challenges, amid a fledgling Tennessee Biotech industry.
Monday, October 06, 2008
BioMimetic Chief Science Officer resigns
In an SEC filing Friday, BioMimetic Therapeutics announced the resignation of Chief Science Officer Charles Hart, citing his desire to "continue to be involved in discovery research." Hart was named in 2004 and held the role during critical phases of the company's efforts to win FDA approval for its products. BioMimetic has struggled recently to recruit patients to participate in key clinical trials, but recently received FDA approval to stay on course. Our earlier reports chronicled BioMimetic's progress and challenges, amid a fledgling Tennessee Biotech industry.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment